Drugs widely known to reduce mortality in patients with HF, such as beta-blockers [41], angiotensin-converting enzyme (ACE) inhibitors and mineralocorticoid antagonists [42], have demonstrated benefits when started in the acute phase of MI, whereas others, such as sacubitril-valsartan, have not [43], raising concerns about the optimal timing for initiating SGLT2 inhibitors after MI at high risk of developing HF. This evidence concerns the gene SLC5A2 and myocardial infarction.